|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Weigelt B, Peterse JL and van 't Veer LJ:
Breast cancer metastasis: Markers and models. Nat Rev Cancer.
5:591–602. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jerusalem G, Rorive A and Collignon J:
Chemotherapy options for patients suffering from heavily pretreated
metastatic breast cancer. Future Oncol. 11:1775–1789. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nakamura S, Yagata H, Ohno S, Yamaguchi H,
Iwata H, Tsunoda N, Ito Y, Tokudome N, Toi M, Kuroi K, et al:
Multicenter study evaluating circulating tumor cells as a surrogate
for response to treatment and overall survival in metastatic breast
cancer. Breast Cancer. 17:199–204. 2010. View Article : Google Scholar
|
|
5
|
Yao YS, Qiu WS, Yao RY, Zhang Q, Zhuang
LK, Zhou F, Sun LB and Yue L: miR-141 confers docetaxel
chemoresistance of breast cancer cells via regulation of EIF4E
expression. Oncol Rep. 33:2504–2512. 2015.PubMed/NCBI
|
|
6
|
Xu F, Wang F, Yang T, Sheng Y, Zhong T and
Chen Y: Differential drug resistance acquisition to doxorubicin and
paclitaxel in breast cancer cells. Cancer Cell Int. 14:5382014.
View Article : Google Scholar :
|
|
7
|
Shuhendler AJ, Prasad P, Zhang RX, Amini
MA, Sun M, Liu PP, Bristow RG, Rauth AM and Wu XY: Synergistic
nanoparticulate drug combination overcomes multidrug resistance,
increases efficacy, and reduces cardiotoxicity in a
nonimmunocompromised breast tumor model. Mol Pharm. 11:2659–2674.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mohell N, Alfredsson J, Fransson Å,
Uustalu M, Byström S, Gullbo J, Hallberg A, Bykov VJ, Björklund U
and Wiman KG: APR-246 overcomes resistance to DOX and doxorubicin
in ovarian cancer cells. Cell Death Dis. 6:e17942015. View Article : Google Scholar
|
|
9
|
Gao JH, Chen FH, Wang L, Wei H and Meng
SL: YM155 inhibits tumor growth and enhances chemosensitivity to
cisplatin in osteosarcoma. Eur Rev Med Pharmacol Sci. 19:2062–2069.
2015.PubMed/NCBI
|
|
10
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sevignani C, Calin GA, Siracusa LD and
Croce CM: Mammalian microRNAs: A small world for fine-tuning gene
expression. Mamm Genome. 17:189–202. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ambros V: MicroRNA pathways in flies and
worms: Growth, death, fat, stress, and timing. Cell. 113:673–676.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Calin GA, Sevignani C, Dumitru CD, Hyslop
T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M,
et al: Human microRNA genes are frequently located at fragile sites
and genomic regions involved in cancers. Proc Natl Acad Sci USA.
101:2999–3004. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Qiu F, Xiong JP, Deng J and Xiang XJ:
TRIM29 functions as an oncogene in gastric cancer and is regulated
by miR-185. Int J Clin Exp Pathol. 8:5053–5061. 2015.PubMed/NCBI
|
|
15
|
Tian X, Xu L and Wang P: MiR-191 inhibits
TNF-α induced apoptosis of ovarian endometriosis and endometrioid
carcinoma cells by targeting DAPK1. Int J Clin Exp Pathol.
8:4933–4942. 2015.
|
|
16
|
Toraih EA, Mohammed EA, Farrag S, Ramsis N
and Hosny S: Pilot study of serum nicroRNA-21 as a diagnostic and
prognostic biomarker in Egyptian breast cancer patients. Mol Diagn
Ther. 19:179–190. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kaboli PJ, Rahmat A, Ismail P and Ling KH:
MicroRNA-based therapy and breast cancer: A comprehensive review of
novel therapeutic strategies from diagnosis to treatment. Pharmacol
Res. 97:104–121. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCT method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
19
|
Czeczuga-Semeniuk E, Bielawski T,
Lemancewicz D, Rusak M and Wołczyński S: Vitamin A family
compounds, estradiol, and docetaxel in proliferation, apoptosis and
immunocytochemical profile of human ovary endometrioid cancer cell
line CRL-11731. Folia Histochem Cytobiol. 47:S127–S135. 2009.
|
|
20
|
Prathapan A, Vineetha VP and Raghu KG:
Protective effect of Boerhaavia diffusa L. against mitochondrial
dysfunction in angiotensin II induced hypertrophy in H9c2
cardiomyoblast cells. PLoS One. 9:e962202014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zahedifard M, Faraj FL, Paydar M, Yeng
Looi C, Hajrezaei M, Hasanpourghadi M, Kamalidehghan B, Abdul Majid
N, Mohd Ali H and Ameen Abdulla M: Synthesis, characterization and
apoptotic activity of quinazolinone Schiff base derivatives toward
MCF-7 cells via intrinsic and extrinsic apoptosis pathways. Sci
Rep. 5:115442015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Frank DO, Dengjel J, Wilfling F,
Kozjak-Pavlovic V, Häcker G and Weber A: The pro-apoptotic BH3-only
protein Bim interacts with components of the translocase of the
outer mitochondrial membrane (TOM). PLoS One. 10:e01233412015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Geserick P, Wang J, Feoktistova M and
Leverkus M: The ratio of Mcl-1 and Noxa determines ABT737
resistance in squamous cell carcinoma of the skin. Cell Death Dis.
5:e14122014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang B, Hsu SH, Majumder S, Kutay H, Huang
W, Jacob ST and Ghoshal K: TGFbeta-mediated upregulation of hepatic
miR-181b promotes hepatocarcinogenesis by targeting TIMP3.
Oncogene. 29:1787–1797. 2010. View Article : Google Scholar :
|
|
25
|
Yan LX, Huang XF, Shao Q, Huang MY, Deng
L, Wu QL, Zeng YX and Shao JY: MicroRNA miR-21 overexpression in
human breast cancer is associated with advanced clinical stage,
lymph node metastasis and patient poor prognosis. RNA.
14:2348–2360. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nakajima G, Hayashi K, Xi Y, Kudo K,
Uchida K, Takasaki K, Yamamoto M and Ju J: Non-coding MicroRNAs
hsa-let-7g and hsa-miR-181b are associated with chemoresponse to
S-1 in colon cancer. Cancer Genomics Proteomics. 3:317–324.
2006.
|
|
27
|
Lee EJ, Gusev Y, Jiang J, Nuovo GJ, Lerner
MR, Frankel WL, Morgan DL, Postier RG, Brackett DJ and Schmittgen
TD: Expression profiling identifies microRNA signature in
pancreatic cancer. Int J Cancer. 120:1046–1054. 2007. View Article : Google Scholar
|
|
28
|
Miller TE, Ghoshal K, Ramaswamy B, Roy S,
Datta J, Shapiro CL, Jacob S and Majumder S: MicroRNA-221/222
confers tamoxifen resistance in breast cancer by targeting
p27Kip1. J Biol Chem. 283:29897–29903. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Giunti L, da Ros M, Vinci S, Gelmini S,
Iorio AL, Buccoliero AM, Cardellicchio S, Castiglione F, Genitori
L, de Martino M, et al: Anti-miR21 oligonucleotide enhances
chemosensitivity of T98G cell line to doxorubicin by inducing
apoptosis. Am J Cancer Res. 5:231–242. 2015.PubMed/NCBI
|
|
30
|
Jiang C, Long J, Liu B, Xie X and Kuang M:
Mcl-1 Is a novel target of miR-26b that is associated with the
apoptosis induced by TRAIL in HCC cells. Biomed Res Int.
2015:5727382015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yin W, Nie Y, Zhang Z, Xie L and He X:
miR-193b acts as a cisplatin sensitizer via the caspase-3-dependent
pathway in HCC chemotherapy. Oncol Rep. 34:368–374. 2015.PubMed/NCBI
|
|
32
|
Kivits RA and Furneaux C: BIM: Enabling
sustainability and asset management through knowledge management.
Scientific World Journal. 2013:9837212013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Youle RJ and Strasser A: The BCL-2 protein
family: Opposing activities that mediate cell death. Nat Rev Mol
Cell Biol. 9:47–59. 2008. View
Article : Google Scholar
|
|
34
|
O'Connor L, Strasser A, O'Reilly LA,
Hausmann G, Adams JM, Cory S and Huang DC: Bim: A novel member of
the Bcl-2 family that promotes apoptosis. EMBO J. 17:384–395. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Faber AC, Corcoran RB, Ebi H, Sequist LV,
Waltman BA, Chung E, Incio J, Digumarthy SR, Pollack SF, Song Y, et
al: BIM expression in treatment-naive cancers predicts
responsiveness to kinase inhibitors. Cancer Discov. 1:352–365.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Shao YY, Chang YL, Huang CY, Hsu CH and
Cheng AL: The germline BIM deletion polymorphism is not associated
with the treatment efficacy of sorafenib in patients with advanced
hepatocellular carcinoma. Oncology. 85:312–316. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lee JH, Lin YL, Hsu WH, Chen HY, Chang YC,
Yu CJ, Shih JY, Lin CC, Chen KY, Ho CC, et al: Bcl-2-like protein
11 deletion polymorphism predicts survival in advanced
non-small-cell lung cancer. J Thorac Oncol. 9:1385–1392. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Weber K, Harper N, Schwabe J and Cohen GM:
BIM-mediated membrane insertion of the BAK pore domain is an
essential requirement for apoptosis. Cell Reports. 5:409–420. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Park C, Hong SH, Kim GY and Choi YH:
So-Cheong-Ryong-Tang induces apoptosis through activation of the
intrinsic and extrinsic apoptosis pathways, and inhibition of the
PI3K/Akt signaling pathway in non-small-cell lung cancer A549
cells. BMC Complement Altern Med. 15:1132015. View Article : Google Scholar : PubMed/NCBI
|
